Systemic Sclerosis: Autoantibody Profiles Linked to Cancer Risk

Multi-Center Cohort Analysis of Systemic Sclerosis Cancer Risks

Systemic sclerosis already carried known associations with heightened malignancy rates. However, according to the abstract presented by A. Mahajan and colleagues, the precise patterns and their direct relationship to autoantibody statuses remained poorly characterized until now. To uncover these patterns, the research team conducted a multi-center cohort study examining five-year cancer incidences using electronic medical record data from 128 healthcare organizations gathered between 2016 and 2024.

The investigators compared adult patients with systemic sclerosis against matched control cohorts featuring patients with seborrheic keratosis. To ensure statistical reliability, the study employed a propensity score matching approach utilizing a greedy nearest neighbor algorithm. This balanced both groups across critical demographic factors and baseline health characteristics, including age, sex, race, ethnicity, and underlying comorbidities.

Following this rigorous matching process, the final analysis included 66,637 patients in each cohort. The demographic breakdown showed a mean patient age of 55.5 years with a standard deviation of 16.5, and 81.0% of the cohort identified as female. To control for confounding variables, the researchers also tracked negative control outcomes such as varicose veins and head lacerations, confirming no unexpected distortions in the dataset.

Elevated Risks for Hematologic and Solid-Organ Malignancies

The data revealed that patients with systemic sclerosis face a general risk increase for any cancer compared to matched controls, yielding a hazard ratio of 1.17 with a 95% confidence interval ranging from 1.11 to 1.23, according to the findings. Hematologic cancers showed a particularly pronounced increase, registering an overall hazard ratio of 1.68. Within this category, specific blood-related malignancies spiked dramatically:

• Multiple Myeloma: Hazard ratio of 2.13 (95% CI 1.61–2.81).
• Myelodysplastic Syndromes: Hazard ratio of 2.03 (95% CI 1.49–2.77).

Solid-organ cancers also occurred at elevated rates, with the overall solid-organ hazard ratio landing at 1.23. Among individual solid tumors, esophageal cancer demonstrated the highest relative risk, showing a nearly fourfold increase with a hazard ratio of 3.96. Lung cancer followed closely behind as a major area of concern, recording a hazard ratio of 2.32.

Autoantibody Stratification Reveals Unique Vulnerabilities

A primary objective of the study was breaking down these cancer risks according to specific autoantibody statuses available from clinical laboratory testing. The results indicate that a patient’s autoantibody profile heavily dictates which malignancies they are most likely to develop:

• Anti-Scl-70 Positive: Patients carrying these autoantibodies exhibited an increased overall cancer risk, with a hazard ratio of 1.40.
• RNA Polymerase III Positive: This subgroup demonstrated significantly higher rates of hematologic cancers specifically, registering a hazard ratio of 2.56.
• Anti-Centromere Positive: Patients in this group showed no elevated risks for the cancers studied, and interestingly demonstrated a decreased risk of melanoma with a hazard ratio of 0.26.

Zangenah, M. Vazquez-Machado, A. LaChance, and J. Sparks. Several authors disclosed industry relationships within the abstract documentation: A. LaChance reported relationships with Johnson & Johnson, Merck, and Pfizer, while J. Sparks reported relationships with Boehringer Ingelheim, Bristol-Myers Squibb, and Janssen. These findings underscore the critical need for clinicians to monitor systemic sclerosis patients through tailored cancer surveillance programs built around individual autoantibody biomarkers.